Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$20.87
-0.4%
$20.26
$13.40
$25.23
$3.50B0.641.97 million shs1.27 million shs
Arcellx, Inc. stock logo
ACLX
Arcellx
$66.00
-1.7%
$63.22
$47.86
$107.37
$3.63B0.28609,454 shs139,219 shs
Merus N.V. stock logo
MRUS
Merus
$52.70
-2.1%
$49.89
$33.19
$62.98
$3.64B1737,305 shs175,892 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$12.41
-2.5%
$11.12
$8.18
$29.56
$943.39M2.15835,181 shs388,891 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%-5.29%-4.69%+43.39%+29.88%
Arcellx, Inc. stock logo
ACLX
Arcellx
0.00%+2.98%-1.18%+18.79%+24.32%
Merus N.V. stock logo
MRUS
Merus
0.00%+1.60%-4.22%+44.00%+0.94%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
0.00%+9.36%-0.39%+30.97%-34.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.685 of 5 stars
4.43.00.00.03.24.22.5
Arcellx, Inc. stock logo
ACLX
Arcellx
2.3047 of 5 stars
3.53.00.00.01.12.50.0
Merus N.V. stock logo
MRUS
Merus
2.021 of 5 stars
3.61.00.00.02.12.50.0
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1.6154 of 5 stars
3.40.00.00.03.80.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.71
Moderate Buy$27.8833.55% Upside
Arcellx, Inc. stock logo
ACLX
Arcellx
3.07
Buy$111.2368.53% Upside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6460.60% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.83
Moderate Buy$30.18143.14% Upside

Current Analyst Ratings Breakdown

Latest NRIX, MRUS, ACAD, and ACLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$37.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
6/23/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.00
6/17/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$110.00
6/16/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
6/6/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.00
6/5/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/5/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Hold$18.00 ➝ $23.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.65$0.70 per share29.72$4.40 per share4.74
Arcellx, Inc. stock logo
ACLX
Arcellx
$107.94M33.70N/AN/A$8.41 per share7.85
Merus N.V. stock logo
MRUS
Merus
$36.13M100.95N/AN/A$9.46 per share5.57
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$54.55M17.35N/AN/A$7.44 per share1.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3715.2527.464.5122.97%17.46%10.75%8/5/2025 (Estimated)
Arcellx, Inc. stock logo
ACLX
Arcellx
-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$193.57M-$2.80N/AN/AN/A-369.40%-47.49%-36.10%7/10/2025 (Estimated)

Latest NRIX, MRUS, ACAD, and ACLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/10/2025Q2 2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.73N/AN/AN/A$16.26 millionN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/8/2025Q1 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million
5/7/2025Q1 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.10$0.11+$0.01$0.11$239.32 million$244.32 million
4/8/2025Q1 2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Arcellx, Inc. stock logo
ACLX
Arcellx
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.88
2.80
Arcellx, Inc. stock logo
ACLX
Arcellx
N/A
4.93
4.93
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
6.26
6.26

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Arcellx, Inc. stock logo
ACLX
Arcellx
96.03%
Merus N.V. stock logo
MRUS
Merus
96.14%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
28.30%
Arcellx, Inc. stock logo
ACLX
Arcellx
8.35%
Merus N.V. stock logo
MRUS
Merus
4.57%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
7.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510167.36 million120.00 millionOptionable
Arcellx, Inc. stock logo
ACLX
Arcellx
8055.11 million50.51 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
30076.24 million70.60 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Increase Earnings Estimates for NRIX
What is HC Wainwright's Forecast for NRIX FY2026 Earnings?
Nurix Therapeutics (NRIX) to Release Earnings on Thursday
Nurix Therapeutics, Inc. (NRIX) - Yahoo Finance
NRIX Nurix Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.87 -0.08 (-0.37%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx stock logo

Arcellx NASDAQ:ACLX

$66.00 -1.16 (-1.73%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Merus stock logo

Merus NASDAQ:MRUS

$52.70 -1.12 (-2.08%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$12.41 -0.32 (-2.51%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.